- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2022–2027 · program · P50
Biostatistics Core
Beow Yong Yeap · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · program · P50
Career Enhancement Program
Daniel Botelho Costa · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · program · P01
Defining the T Cell Mediators of Clinical Response in Chronic GVHD
Leslie S Kean · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · program · P50
Project 1
Alice T Shaw · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2025 · research · R01
DMS/NIGMS 1: Statistical modeling and estimation of cellular population dynamics
Thomas Mcdonald · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · research · R01
CDK4/6 inhibition during CD8 T cell priming potentiates memory formation in mice and humans
Stephanie Dougan · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · cooperative agreement · UM1
Molecular phenotyping of ~100,000 coding variants across Mendelian disease genes
Marc Vidal · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · research · R35
Mechanisms of eIF3-mediated translation regulation
Amy Si-Ying Lee · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2024 · grant · DP2
Discovery of cGAS-like signaling enzymes in innate immunity and disease
Philip J Kranzusch · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2023 · career development · K99
Translational regulation of PGC1alpha and oxidative metabolism
Phillip Anthony Dumesic · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2024 · grant · DP2
Hijacking the T cell machinery for logic-gated CAR T cell control
Robbie G. Majzner · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · research · R01
Optimizing Therapeutic STING Agonism in Triple Negative Breast Cancer
Thanh Uyen Barbie · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2023 · research · R56
Mitochondrial Protein Translation Signaling and Survival Mechanisms
Pere Puigserver · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · research · R01
Mechanisms of immune evasion in T-cell acute lymphoblastic leukemia and its therapeutic implications
Birgit Knoechel · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · grant · D43
BIDIRECTIONAL TRAINING TO ENHANCE CANCER RESEARCH CAPACITY IN AFRICA
Timothy R Rebbeck · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · grant · PCRP
Integrative Dissection of Germline Genomic Features Driving Cancer Risk, Disease Progression, and Response to Therapy in Prostate Cancer
Saud Aldubayan · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2021–2026 · career development · K08
Characterizing the XRN1 exoribonuclease as a therapeutic target in non-small cell lung cancer
Tao Zou · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · research · R01
Defining epigenetic mechanisms in NPM1c mutant leukemia
Scott A Armstrong · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2023 · grant · MRP
A Chemopreventative Strategy to Intercept Melanomagenesis Associated with Red Hair/Pale Skin
Rizwan Haq · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2021–2026 · research · R01
Structure-activity relationships governing mammalian SWI/SNF chromatin remodeling activity as a function of chromatin state
Cigall Kadoch · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2024 · grant · KCRP
Engineering Chimeric Antibody Signaling and Secreting (CASS) B Cells to Achieve ccRCC Cures
Wayne Marasco · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2021–2026 · research · R37
Targeting vulnerabilities of PPM1D-mutant gliomas
Pratiti Bandopadhayay · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2023 · research · R03
A Preventive Care Approach to Mitigate the Impact of Pediatric ALL Treatment on Sleep
Kira O. Bona · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2024 · fellowship · F32
Mechanisms and therapeutic evaluation of splicing modulation for cohesin-mutant myelodysplastic syndromes
Emily Wheeler · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2024 · career development · K00
Exploiting Oncogenic Chromatin Regulators in Cancer Initiation and Progression
Usman Hyder · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · research · R37
Targeting vulnerabilities of PPM1D-mutant gliomas
Pratiti Bandopadhayay · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · research · R37
Targeting vulnerabilities of PPM1D-mutant gliomas
Pratiti Bandopadhayay · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2025 · research · R01
A Stakeholder Informed Randomized Trial of Pretest Video Education vs Standard Genetic Counseling for Cancer Patients: Evaluating the Impact on Patients, Providers and Practices
Huma Q Rana · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2023 · research · R01
Development, Optimization and Preclinical Modeling of Hematopoietic Stem Cell Gene Editing for the Treatment of RAG1 Immunodeficiency
Pietro Genovese · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · research · R01
Elucidation of the genetic mechanisms driving prostate tumorigenesis through integrative computational and functional approaches
Matthew L Freedman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · grant · D43
BIDIRECTIONAL TRAINING TO ENHANCE CANCER RESEARCH CAPACITY IN AFRICA
Timothy R Rebbeck · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · career development · K08
The Impact of Donor Hematopoietic DNMT3A Mutations in Stem Cell Transplant Recipients
Christopher James Gibson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2023 · career development · K99
Integrative Prediction of Therapeutic Response in T-cell Lymphoma by Omic and Spatial Modeling
Ajit Johnson Nirmal · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · career development · K08
Elucidating the impact of DNA hypomethylation on genome organization and anti-tumor transcriptional programs
Sarah E Johnstone · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · career development · K08
Insights from somatic genomics lead to novel therapeutic targets in inherited bone marrow failure syndromes: Shwachman-Diamond Syndrome as a model.
Alyssa Kennedy · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · research · R01
Genetic Predisposition to Chronic Lymphocytic Leukemia (CLL)
Jennifer R Brown · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · research · R01
Genetic Predisposition to Chronic Lymphocytic Leukemia (CLL)
Jennifer R Brown · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2025 · research · R01
A Stakeholder Informed Randomized Trial of Pretest Video Education vs Standard Genetic Counseling for Cancer Patients: Evaluating the Impact on Patients, Providers and Practices
Huma Q Rana · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2023 · career development · K99
Integrative Prediction of Therapeutic Response in T-cell Lymphoma by Omic and Spatial Modeling
Ajit Johnson Nirmal · Dana-Farber Cancer Institute · funded by National Institutes of Health
2021–2026 · cooperative agreement · UM1
Molecular phenotyping of ~100,000 coding variants across Mendelian disease genes
Marc Vidal · Dana-Farber Cancer Institute · funded by National Institutes of Health
